trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,lung,4', 't-dxd', 'lung', 'nsclc', 'destiny,lung02', 'sclc', 'trastuzumab deruxtecan']
destiny-lung02 compared two doses of trastuzumab deruxtecan (t-dxd) in #her2 previously treated nsclc (5.4 mg/kg vs 6.4 mg/kg): rr 58% and dor 8.7m at the lower dose compared to 43% at 6.4 mg/kg. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him